Intestinal Permeability and Gastroparesis

Overview

About this study

The purpose of this study is to investigate, using several novel techniques, potential pathophysiologic abnormalities that could lead to the development of symptoms of gastroparesis (GP).  The global hypothesis is that patients with GP will be more likely than controls to have abnormalities in duodenal intestinal permeability.

 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients (18-75 years old).
  • Men and women.
  • Patients with gastroparesis.

Exclusion Criteria:

  • Patients will be excluded from the study if symptoms are thought to represent an organic disorder (e.g., peptic ulcer disease, hepatitis, pancreatitis, inflammatory bowel disease, a known malignancy, radiation-induced injury, an active infection, vasculitis, celiac disease), GERD, esophagitis, eosinophilic esophagitis or H. pylori.
  • Patients with uncontrolled diabetes mellitus (hemoglobin A1C > 10).
  • Patients with prior surgery to the esophagus, stomach or duodenum.
  • Patients taking opioids, steroids, anti-histamines, immunosuppressive agents, NSAIDs, or mast cell stabilizing agents within the prior 3 months. 
  • Patients currently prescribed aspirin or aspirin regimens for other clinical reasons. 
  • Patients with known allergies to lactulose: mannitol will be excluded.

Eligibility last updated 8/25/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

David Cangemi, M.D.

Open for enrollment

Contact information:

David Cangemi M.D.

(904) 953-6970

Cangemi.David@mayo.edu

More information

Publications

Publications are currently not available